Filing Details
- Accession Number:
- 0000950170-24-041432
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-04-03 19:36:56
- Reporting Period:
- 2024-04-01
- Accepted Time:
- 2024-04-03 19:36:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1745999 | Beam Therapeutics Inc. | BEAM | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1786304 | M. John Evans | C/O Beam Therapeutics Inc., 238 Main Street Cambridge MA 02142 | Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-04-01 | 18,102 | $32.13 | 1,058,343 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-04-03 | 99,336 | $0.00 | 99,336 | $0.67 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-04-03 | 53,965 | $0.00 | 53,965 | $4.22 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 99,336 | 2024-04-03 | 2028-05-08 | No | 4 | A | Direct |
| 53,965 | 2024-04-03 | 2029-02-13 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 103,000 | Indirect | By John M. Evans, III 2018 Irrevocable Trust |
Footnotes
- These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- On May 8, 2018, the Reporting Person was granted an option to purchase 99,336 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
- On February 13, 2019, the Reporting Person was granted an option to purchase 53,965 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 53,965 shares.
Billionaire Hedge Funds
